Fourth edition
Join the leading event for biotech in Central Europe
- 23/9/2026
- Prague, National House Vinohrady
- 20+ Speakers
What can you look forward this year?
400+ participants from the biotech industry including key decision-makers
Panel discussions and workshops
on trending topics
Pitch session featuring innovative
start-ups and R&D teams
Inspiring keynote
talks
Partnering system for scheduling
one-on-one meetings
Valuable networking opportunities and welcoming atmosphere
Program
Welcome to the 4th edition
Claire Skentelbery, EuropaBio
Investor Panel Discussion
☕ Coffee Break
Chris Bladen, Zymedyne Therapeutics
First batch of pitching teams
🍽️ Lunch
Miruna-Cristina Gala, EIF
Second batch of pitching teams
Global biotech trends
Poster Session & Coffee Break
Markus Gerhard, TUM Venture Labs
TechBio Panel Discussion
Closing Remarks & Pitch Awards
🎉 Networking · until 21:00
Register your project for
Pitch & Poster Session
Our speakers
Iwona Cymerman is a scientist turned entrepreneur and VC. As Co-Founder and General Partner at AGX, she backs deep tech founders from Poland and neighboring markets at the earliest stages, helping transform breakthrough technologies into globally competitive companies.
Kamila Seberová is the main contact for the Life Sciences team in Prague and coordinates the firm-wide Life Sciences initiative. Kamila has an extensive experience advising major multinational and domestic clients in the pharmaceutical, medical device, and healthcare sectors and has a strong track record in regulatory compliance, including matters involving pharmaceuticals, medical devices, food supplements, clinical trials, price regulation, and the advertising and marketing of medicinal products. She regularly represents clients in regulatory proceedings before the State Institute for Drug Control, the Ministry of Health, and administrative courts, and provides strategic advice in patent and unfair competition disputes. Kamila also advises on commercial agreements with healthcare providers, distributors, and industry partners, and supports clients in M&A transactions, joint ventures, and broader corporate matters in the life sciences sector.
Boldizsár Elek is VP of Scientific Operations at Turbine, whose Virtual Lab lets researchers test millions of ideas beyond the constraints of the physical lab. He leads Turbine’s Solutions department, translating simulations into delivery across pharma collaborations. Having previously headed Turbine’s pipeline strategy, he bridges computational biology, drug discovery, and commercial partnerships to bring AI-powered biomedical research closer to patients.
Anela brings 10+ years of experience in venture capital and management consulting. With a PhD in Neuroscience, she leads investments in innovative drug development and supports company building, portfolio management, and board governance. She is actively engaged in advancing the DACH biotech ecosystem.
Claire holds a degree in agriculture and a PhD in biochemistry and has worked in the leadership of scientific associations for 20 years. She started her career within the UK Cambridge biotech cluster and was a co-founder and Manager of the Council of European BioRegions, a network of biotechnology clusters across Europe in Brussels, she also took on the role of SG for the European Biotechnology Network (EBN) in 2012, working across sectors, organisations and countries as part of the EBN mission to facilitate collaboration.
In 2017, Claire became Director General of the globally-focussed Nanotechnology Industries Association (NIA) which she successfully led until November 2020 when she joined EuropaBio as Director General. In addition to her current role at EuropaBio, she is also the Chair of the International Council of Biotechnology Associations (ICBA) and Governing Board Member for the Innovative Health Initiative (IHI).
She has a driving interest in collaboration across the value chain to develop the business of science, and the role of internationally networked policies, programmes, skills, finance and infrastructures to create a strong landscape.
Marcus Gerhard studied medicine in Heidelberg and Hamburg and earned his MD in 1996. From 1997 to 2004 he completed his medical training leading to German medical board certification in internal medicine in the Department of Internal Medicine at Klinikum rechts der Isar. From 2006 he headed a research group in the Department of Internal Medicine at TUM, where he also acquired his postdoctoral teaching qualification (habilitation) in internal medicine in 2009. In 2010 he was appointed associate professor of medical microbiology and immunology at the Institute for Medical Microbiology and Immunology, a unit within TUM. He also serves as academic director of the TUM Venture Lab Healthcare, TUM`s biotech incubator.
The research work of Professor Gerhard explores how pathogens interact with the host in gastrointestinal infections. Professor Gerhard’s research group investigates the mechanisms that suppress the immune response of the host to allow the establishment of chronic infection as well as inflammatory factors involved in the development of cancer, in order to leverage this know-how for the development of novel preventive and therapeutic strategies.
Prof. Gerhard has published > 120 papers, many in prestigious journals such as Nature Medicine, Nature Microbiology, Gastroenterology, GUT, NEJM etc.
Previously, Barbara was Chair of Puridify until its acquisition by GE (Cytiva). She was CEO of Stabilitech and prior to that was Commercial Director at Arrow Therapeutics until its acquisition by AstraZeneca.
Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School.
Chris Bladen received his PhD in Molecular Neuroscience from the Hotchkiss Brain Institute, University of Calgary in 2014. His thesis was based on using Electrophysiology and Molecular Biology to develop drugs and small molecules for Pain and Epilepsy research as well as other clinical purposes. He has a B.Sc. in Freshwater Chemistry and a degree in Environmental management and has extensive experience in both academia and industry. His previous work experience includes several years as an independent environmental consultant for the oil and gas industry in Alberta and several years working in the biopharma industry. He has developed a world-wide collaborative network in the fields of Electrophysiology, Molecular Biology and Drug design. In addition to being CEO of Zymedyne therapeutics, he is currently an (Online) Lecturer at Macquarie University’s Department of Biomedical Sciences, where he teaches Pharmacology and conducts research into the therapeutic potential of Synthetic and Phyto Cannabinoids.
Jared Auclair serves as the Dean of the College of Professional Studies. Appointed in December 2024, Jared leads all academic and administrative functions of the college.
With more than a decade of experience at Northeastern, starting first as a post-doc and most recently, Vice Provost Research Economic Development and Director of Bioinnovation, Jared is a champion of innovation and collaboration and deeply values the promise that the College of Professional Studies brings to students as one of Northeastern’s most diverse and dynamic colleges committed to meet students where they are.
Prior to his role as Vice Provost Research Economic Development, Jared served as the Associate Dean of Professional Programs and Graduate Affairs in the College of Science, and still holds a faculty appointment in the Department of Chemistry and Chemical Biology. His past experience with the College of Professional Studies includes leadership on a variety of economic and workforce development and research programs, including PlusOne, a dynamic program that gives students the opportunity to accelerate their education by earning both a bachelor’s and master’s degree in five years.
With an extensive leadership background, Jared’s passion for progress drives essential strategic initiatives for the College of Professional Studies. His focus on strengthening the connections between education, research, and community, along with fostering a global mindset is core to the College of Professional Studies’ commitment to delivering a world-class experiential education tailored to students’ needs.
Prior to joining Northeastern, Jared held a variety of research and consulting roles for leading biopharmaceutical firms. He holds a bachelor’s degree in biotechnology from Worcester Polytechnic Institute and a PhD in Biomedical Science from the University of Massachusetts Medical.
Buy Tickets
Sponsorship
FAQ
Where is the Prague.bio Conference 2026 taking place?
As last year, the Prague.bio Conference will take place at National House Vinohrady, Náměstí Míru 820/9, 120 00 Prague, Czech Republic.
When is the conference taking place and what time does it start?
The conference is scheduled for Wednesday, September 23, 2026. The program is set to begin at 9:00 AM, with registration opening at 8:30 AM.
How do I get to the National House Vinohrady?
You can use various modes of public transportation. The venue is centrally located in Prague, making it easily accessible. The nearest metro station is „Náměstí Míru“, which serves Line A (Green). Additionally, there are multiple tram lines stoping at Náměstí Míru (tram no. 4, 10, 13, 16, 22).
Is parking available?
No. The nearest large parking facilities would be at the Flora shopping centre or next to the Opera building. Remember to check the availability and rates of the parking facility in advance.
Do you have partnering at the conference?
Yes. Each participant will receive a link to access our partnering app provided by Brella. There is also a dedicated space for partnering at the venue.
Will catering be provided?
Yes! During the day, lunch and dinner will be provided, along with drinks and light refreshments available throughout the day.
Is there a conference hotel?
Although we do not have a dedicated conference hotel, there are quite many options in the neighbourhood and Prague city centre. Business hotels within the walking distance are for example Clarion Hotel Prague City (Tylovo náměstí 15/3) or Le Palais Art Hotel Prague (U Zvonařky 1).
What time does the conference end?
The conference programme concludes at 6:00 PM and will be followed by a networking dinner. The doors of the conference will officially close at 9:00 PM.
In what language will the conference be conducted?
In English, and translation into Czech is not provided.
Will it be possible to purchase a ticket on site?
No, you need to purchase tickets in advance. Tickets can be acquired through our website.
I have purchased a ticket and will not be able to come. Can I get a refund?
Unfortunately, refunds are not possible. We would be pleased to transfer your ticket to a colleague, though.
Will there be an online stream of the conference?
At this time, we are not considering a live stream from the event. Also no recordings of the conference will be available after it concludes.
Partners
ORGANISERS
CO-ORGANISERS
GENERAL PARTNER
gold partners
MAIN PARTNERS
media partners
AUSPICES
VISIBILITY PARTNERS
CATERING PARTNER
FUNDED BY
Get in touch
Contact us via the contact form